Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent/IASO Candidate is First BCMA CAR-T Approved in China for Multiple Myeloma

publication date: Jul 5, 2023

Suzhou Innovent and Nanjing’s IASO Bio were approved to launch their partnered BCMA CAR-T in China as a fourth-line therapy for multiple myeloma. The drug, which will be launched with the name Fucaso® (equecabtagene autoleucel, is the first BCMA-directed CAR T cell therapy approved in China for adult patients with relapsed or refractory multiple myeloma (RRMM). Fucaso® uses a lentivirus as a gene vector to transfect autologous T cells and contains 4-1BB-mediated co-stimulation and CD3ζ activation domains. It produced a complete response in 74% of the trial patients. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital